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Cerebrospinal ﬂuid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment
who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16
nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated
protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau),
phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was signiﬁcantly increased in the AD group as
compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal ﬂuid sample revealed that
both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD
biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.
1.Introduction
Alzheimer’s disease is a chronic neurodegenerative disorder
that causes progressive decline in memory and other higher
cortical functions [1]. The underlying neuropathological
molecular changes are apparently mirrored by elevated ce-
rebrospinal ﬂuid (CSF) levels of total Tau (tTau) and phos-
phorylated Tau (pTau) and a reduced concentration of the
beta-amyloid 42 peptide (Aβ42). The increase in total Tau is
believed to reﬂect the intensity of the neuronal degeneration,
while pTau may indicate the phosphorylation state of the
T a up r o t e i n( f o rr e v i e w ,s e e ,e . g . ,[ 2]). Biomarkers can
complement the clinical disease diagnosis which is currently
mainly based on functional symptoms, and they may prove
to be helpful in identifying individuals at an early disease
stageorathighrisk[3,4].Thiswillbeparticularlyimportant
once novel disease-modifying therapeutics will be available,
w h i c hc a nb ee x p e c t e dt op r o d u c em o s tb e n e ﬁ tw h e n
applied early. Biomarkers that reliably report disease-related
pathophysiological processes may also be useful to monitor
drug eﬃcacy in clinical trials.
An early event in the development of the neuroﬁbrillary
changesinAlzheimer’sdiseaseisthepathologicalhyperphos-
phorylation of Tau [5]. The underlying biochemical mecha-
nisms are poorly understood, and providing deeper insight
is a topic of high relevance. Various kinases have been
proposed to be possibly implicated, one of which is the MAP
kinase ERK2 (reviewed in [6, 7]). In a recent study, we have
demonstrated the possibility to detect soluble ERK1/2 in
CSF from patients with neuropsychiatric disorders, and we2 International Journal of Alzheimer’s Disease
have laid the methodological groundwork for CSF-ERK1/2
quantiﬁcations with a 96-well electrochemiluminescence
monoplex immunoassay [8]. As a logical extension of this
pilot study, we report here the measurement of ERK1/2
in CSF samples from 33 patients with Alzheimer dementia
(AD), 21 patients with mild cognitive impairment who
converted to AD during followup (MCI-AD), 25 patients
with stable mild cognitive impairment (stable MCI), and
an age-matched reference cohort (n = 16) consisting of
nondemented subjects (ND).
2.MaterialsandMethods
2.1. Patients and Control Subjects. All study procedures were
approved by the respective local ethics committees, and
the patients or their legal caregivers gave their informed
consent. At baseline, a comprehensive medical history was
taken, and the patients underwent thorough physical, neu-
rological, and psychiatric examination. For each patient,
a computed tomography or an MRI scan was recorded.
Alzheimer dementia (AD) was diagnosed according to the
NINCDS-ADRDA criteria [9]. Mild cognitive impairment
(MCI)wasdiagnosed,accordingtothePetersencriteria[10],
if a patient had an objective deﬁciency in one or more
cognitive domains (below 1,5 SD compared to an age-, sex-,
and education-matched control cohort) but whose general
cognitive functioning and whose activities of daily living
were not impaired.
The subjects included in this study were categorized into
four groups according to clinical and neuropsychological
criteria: (1) patients with Alzheimer dementia (AD, n =
33); (2) patients who fulﬁlled the Petersen criteria for MCI
[10] and converted to clinical AD during follow-up (MCI-
AD, n = 21; average time to conversion 30 months;
range: 12–59 months); (3) patients with MCI who remained
stable during the follow-up period (MCI-stable, n = 25;
average follow-up time: 43 months; range: 8–78 months);
(4) nondemented individuals referring to the centers for
symptoms or other neurological diseases who underwent
lumbarpuncturefordiagnosticreasons(headache,suspected
myelopathy, etc.) (ND n = 16). The ND group included 4
individuals (“controls”) who were examined for symptoms
but were later found to be neurologically healthy and one
person who fulﬁlled the MCI diagnosis at baseline but
was later found out to be cognitively healthy. The clinical
diagnoses were made blinded to the biomarker results.
For the assessment of cognitive dysfunction’s severity, the
Mini-Mental Status Examination (MMSE) was used [11].
MMSE scores were not available for 7 (out of 16) of the
ND subjects who did not show signs of memory decline
according to the clinical neurological examination, and for
4 (out of 33) AD patients. As additional neuropsychological
testing, MODA (Milan Overall Dementia Assessment [12])
was performed in Perugia. In Kuopio, a set of diﬀerent
neuropsychological tests was applied to speciﬁcally test the
diﬀerent cognitive domains. The complete list of tests has
already been described elsewhere [13]. Neuropsychological
assessment at both sites comprised testing of memory,
language, visuospatial skills, attention, orientation, and ex-
ecutive functions. The MODA, which was used in Perugia,
furthermore included performance in the activities of daily
living as reported by a near relative.
2.2. CSF Samples. The CSF samples were collected in Pe-
rugia, Italy (n = 45) and Kuopio, Finland (n = 50).
CSF was taken by lumbar puncture and processed according
to standardized procedures as described elsewhere [13–15].
After taking CSF for routine tests, a volume of ∼10–12mL
of CSF was collected in polypropylene tubes and centrifuged
to remove cells. The supernatant (“CSF”) was aliquoted
and frozen at −80◦C within one hour after sampling. CSF
samplescontainingmorethan500erythrocytesperμL(prior
to centrifugation) were excluded from the analysis.
2.3. ELISA Measurements of Aβ42, Total Tau, and Phospho-
Tau (pT181). CSF biomarkers were determined by ELISA
method (Innotest hTau-Ag, Innotest pTau181-Ag, Innotest
β-amyloid 1–42, Innogenetics NV, Gent, Belgium). The
measurements were performed in the Clinica Neurologica,
University of Perugia, Italy and in the Department of
Neurology, University of Kuopio, Finland. The tTau, pTau,
and Aβ42 data were collected in the context of other studies,
and these biomarker results have been published before, at
least in parts [13, 16–18]. In the current study, these tTau,
pTau, and Aβ42 data were reevaluated in relation to the
current ERK1/2 measurements.
2.4. ERK1/2 Electrochemiluminescence Monoplex Assay.
ERK1/2 in human CSF was measured with the monoplex
total ERK1/2 whole cell lysate 96-well electrochemilumines-
cence assay (Meso Scale Discovery, Gaithersburg, USA) es-
sentially as described previously [8]. For measuring ERK1/2,
the CSF samples, which had been received frozen on dry
ice and were stored at −80◦C, were thawed, aliquoted, and
refrozen at −80◦C. Immediately prior to the measurements,
the CSF aliquots were thawed for a second time, and 111μL
of each sample was mixed with 18.7μL of an assay buﬀer
concentrate (ﬁnal concentrations in the assay: 100mM
NaCl, 20mM Tris-HCl, pH 7.5, 1mM EDTA, 1mM EGTA,
1% Triton X-100, plus protease inhibitors, and phosphatase
inhibitors(pleasenotethatinourpreviousdescriptionofthe
assay procedure, the ﬁnal concentration of the added NaCl
was erroneously indicated as 150mM [8]). For the duplicate
reads, 50μL per well was analyzed with the MSD total
ERK1/2 monoplex assay according to the manufacturer’s
instructions. The 1.17-fold dilution resulting from the
addition of the assay buﬀer concentrate was considered for
the calculation of the ERK1/2 concentrations. To obtain a
suitable reference sample for calculating the standard curves,
recombinant activated His-tagged ERK2 (Calbiochem)
was initially spiked into a pooled human CSF sample at a
concentration of 480ng/mL (“CSF-stabilized ERK2 stock
solution”). Previous observations had indicated that the
recombinant-activated kinase was relatively stable under
these conditions and could be stored this way in aliquots at
−80◦C. Starting from this ERK2 stock solution in CSF, serialInternational Journal of Alzheimer’s Disease 3
dilutions (250–16000-fold) were prepared in 1x assay buﬀer
(see above) and measured in triplicates against 1x assay
buﬀer. The standard curve for each assay plate was calculated
with the MSD Discovery Workbench 3.0 software. The
lower limit of detection (LLOD) was deﬁned as 3 standard
deviations (SD) above the blank signal (mean of 3 blanks for
each plate). For 9 out of the 95 CSF samples studied here, the
ERK1/2 measurements (means of the duplicate reads) were
below the corresponding LLOD of the respective assay plate.
As a means to include them in the statistical comparison
between the diagnostic groups, these samples are reported
here with an arbitrary value of 39pg/mL corresponding
to a CSF concentration just below the mean LLOD. When
analyzing the correlations between ERK1/2 and age or
classical CSF biomarkers, the 9 ERK1/2 measurements below
LLOD were excluded.
2.5. Statistical Analysis. Statistical tests were performed with
GraphPad Prism 5.01 software (GraphPad Software Inc.
La Jolla, Calif, USA). Nonparametric tests (Kruskal-Wallis
test followed by Dunn’s multiple comparison test and
Spearman correlation test) were applied in most cases, since
D’Agostino-Pearson omnibus K2 test had indicated that
some of the analytes did not follow normal distribution. A
level of P<0.05 was regarded as statistically signiﬁcant. The
actual P levels are given for descriptive purposes.
2.6. Prefractionation of Pooled CSF and Sample Preparation.
To facilitate the subsequent Western blot analysis, pooled
CSF was prefractionated by isoelectric focusing. Ten indi-
vidual CSF samples from AD- and non-AD patients were
combined. 3.25mL of the resulting CSF pool was mixed
with a 10x protease inhibitor cocktail and a 10x phosphatase
inhibitor cocktail (complete Mini and PhosStop, Roche)
to yield 1x inhibitor concentrations. Buﬀer exchange into
“oﬀ-gel rehydration solution” (7M urea, 2M thiourea, 1%
(w/v) DTT, 0.5% (v/v) Pharmalyte) and concentration of
the sample to a ﬁnal volume of ∼100μLw a sa c h i e v e d
with Vivaspin spin concentrators (500μL, 10 000 MWCO,
Sartorius Stedim, G¨ ottingen) according to the manufac-
turer’s protocol. Rehydration solution was added to the
concentrated sample to a ﬁnal volume of 2mL, and the
proteins were separated according to their isoelectric points
(pI) on a 3100 oﬀ-gel fractionator (Agilent). The isoelectric
focusing was performed at a maximum current of 50μA
for 20.000 Vhrs on 13cm long pH 3–10 IPG strips (GE
healthcare). From the resulting 12 fractions, those covering
pH ∼6.5–∼8.5werepooled.Thisway,asubstantialreduction
ofalbuminwasachieved,facilitatingthefurtheranalysis.The
proteinsintheprefractionatedsamplewereprecipitatedwith
trichloroacetic acid and desoxycholate. Brieﬂy, the sample
was mixed with sodium desoxycholate to reach a ﬁnal
concentration of 0.02%. Following 30min incubation on
ice, trichloroacetic acid was added to a ﬁnal concentration
of 15%. After an additional hour on ice, the sample was
centrifuged at 16.000g and 4◦C for 30min. Finally, the
pellet was washed twice with ice cold acetone and air dried.
For SDS-PAGE, the pellet was dissolved in 60μLo fs a m p l e
buﬀer (62.5mM Tris/HCL pH 6.8, 2% (w/v) SDS, 10% (v/v)
Glycerol; 100mM DTT; 0.005% (w/v) bromophenol blue)
for 10min at 95◦C with agitation.
2.7. SDS-PAGE and Western Blotting. The proteins were
separated on 12% T/2.7% C SDS-polyacrylamide gels [19]
and blotted afterwards on PVDF membranes (Millipore)
by semidry transfer at a constant current of 1mA/cm2 for
60min with 25mM Tris, 192mM glycine, and 20% (v/v)
methanol [20]. The membranes were blocked in 2% ECL
Advance blocking agent (GE healthcare) in PBS/0.075%
Tween-20 (PBS-T) for 45min and incubated overnight at
4◦C with antibodies diluted in blocking solution. The fol-
lowingantibodieswereused:rabbitanti-ERK2(C-14)sc-154
(Santa Cruz Biotechnology) (working dilution 100ng/mL);
rabbit anti-ERK1/MAPK3 (RnD Systems) (working dilution
250ng/mL); monoclonal anti-MAP Kinase, activated (clone
MAPK-YT) (Sigma) (working dilution 1:1000). The next
day the membranes were washed with PBS-T and incubated
for 1h at room temperature with horseradish-peroxidase-
coupled secondary antibodies. After washing with PBS-T,
the blots were developed with ECL-plus chemiluminescent
substrate according to the manufacturer’s instructions (GE
Healthcare) and visualized with an Intas Imager (Intas,
G¨ ottingen, Germany).
3. Results
3.1. Diagnostic Groups, Demographical Data, MMSE Scores,
and CSF Biomarkers. A summary of the demographical data
of the 4 diagnostic groups under investigation, as well as
meanMMSEscoresandmedianlevelsoftheCSFbiomarkers
tTau, pTau, and Aβ42 is shown in Table 1.A N O V At e s t
indicated that the mean ages did not diﬀer signiﬁcantly
between the 4 groups (P = 0.0999). The CSF levels (rank
sums) of tTau and pTau were signiﬁcantly higher in the
AD- and the MCI-AD groups than in the MCI-stable and
ND groups (Kruskal-Wallis test followed by Dunn’s multiple
comparison test). Aβ42 was signiﬁcantly lower in AD- and
MCI-AD patients than in MCI-stable and ND subjects (sup-
plementary information, see Figure S1 in Supplementary
Material available online at doi:10.4061/2011/739847).
3.2. Quantiﬁcation of ERK1/2 in CSF. The ERK1/2 con-
centrations in the CSF samples were quantiﬁed with the
total ERK1/2 monoplex electrochemiluminescence assay.
The standard curves were calculated from measurements of
serial dilutions in assay buﬀer of a “CSF-stabilized” ERK2
stock solution (see Materials and Methods). The lower limit
of detection of the assay (LLOD) was deﬁned as 3 standard
deviations (SD) above the blank signal. For the 4 assay plates
employed here, the LLODs were calculated as 31.1pg/mL,
31.4pg/mL, 40.5pg/mL, and 31.7pg/mL, respectively (mean
LLOD ± SD: 33.7 ± 4.6pg/mL). Taking into account the
1.17-folddilutionoftheCSFsamplesresultingfromaddition
of an assay buﬀer concentrate prior to the measurements,
the mean LLOD of the assay corresponded to an ERK1/2
concentration of 39.4pg/mL in undiluted CSF. In total, for4 International Journal of Alzheimer’s Disease
Table 1: Demographical data, MMSE scores, and classical CSF biomarkers∗.
AD MCI-AD MCI-stable ND
n 33 21 25 16
Age (years) Mean 68.4 66 69 63.3
SD 7.6 8.5 7.4 8.4
Gender m/f 15/18 7/14 10/15 6/10
MMSE Mean 19 (n = 29) 26.3 26 27.3 (n = 9)
SD 4.8 1.3 2.5 2.3
tTau (pg/mL) Median 609.8 536.5 210 185.5
25%–75% percentile 372.6–1023 432.2–611.5 145–349.4 176.9–236.6
pTau (pg/mL) Median 106 84 50 45.2
25%–75% percentile 67.5–129.0 73.1–100.3 35.0–66.6 37.2–57.3
Aβ42 (pg/mL) Median 432 397.2 745 794.5
25%–75% percentile 361.5–523.6 344.8–553.2 589.3–981.5 635.8–844.8
∗The CSF levels of tTau, pTau, and Aβ42 are shown here for comparative purposes. The actual measurements were performed within the context of other
studies, and some of the data have been published before [13, 16–18].
this study, 95 CSF samples were included in the analysis.
With regard to the raw signal counts, the coeﬃcient of
variation (CV) between the duplicate reads was on average
2.4% ± 2( m e a n± SD). The maximum CV between the
respective duplicate reads (raw signal counts) observed
in the whole sample was 10.3%, indicating an acceptable
technical assay performance. It should be noted, however,
that the imprecision regarding the individually calculated
CSF-ERK1/2 concentrations for the duplicates was higher
(CV ± SD: 8.5% ± 7.5%, n = 86; the measurements
with mean calculated ERK1/2 levels below the LLOD were
excluded).
3.3. CSF-ERK1/2 Levels in the 4 Diagnostic Groups. For
comparing the CSF-ERK1/2 levels between the 4 diagnostic
groups, those 9 samples with CSF-ERK1/2 measurements
(means from duplicate reads) below the respective assay
plate LLOD are reported here with an artiﬁcially set value
of 39pg/mL. This corresponds to a CSF concentration just
below the mean LLOD (see above). As a group, the AD
patients showed signiﬁcantly higher CSF-ERK1/2 concentra-
tions than the nondemented individuals (P<0.05) and the
stable MCI cohort (P<0.001, Kruskal-Wallis test followed
by Dunn’s multiple comparison test) (Figure 1). The median
ERK1/2 concentrations in the MCI-AD group were in
between those of the AD patients and the stable MCI/ND
cohort. However, as shown in Figure 1,w eo b s e r v e da
clear overlap between groups. As a consequence, the group
comparisons between MCI-AD and MCI-stable, MCI-AD
and AD, MCI-AD and ND, and MCI-stable and ND did
not indicate statistically signiﬁcant diﬀerences (Kruskal-
Wallis test followed by Dunn’s multiple comparison test).
To additionally evaluate whether the large overlap between
the MCI-stable and MCI-AD groups might be attributed
to those MCI-stable subjects in our sample with relatively
short follow-up times, we repeated the calculations with pre-
deﬁned minimum follow-up times for MCI-stable of 24 and
36 months, respectively. Again, only the group diﬀerences
between AD versus MCI-stable and AD versus ND reached
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Figure 1: Scatterplot showing CSF levels of ERK1/2 in the 4
diagnostic groups. The bars indicate medians and the interquartile
ranges. Thered symbols indicate those 9samples withsignals below
LLODthatarereportedherearbitrarilyas39pg/mL.Thediﬀerences
in rank sums between the AD and the ND groups and between AD
and MCI-stable were statistically signiﬁcant: ∗P<0.05, ∗∗∗P<
0.001 (Kruskal-Wallis test followed by Dunn’s multiple comparison
test).LLOD:meanlowerlimitofdetectionofERKinundilutedCSF
(39.4pg/mL).
statistical signiﬁcance (Kruskal-Wallis test with Dunn’s mul-
tiple comparison posttest) (data not shown).
To investigate the possible diagnostic added value of
combiningCSF-ERK1/2levelswithclassicalCSFbiomarkers,
we compared our current results with the CSF concentra-
tions of tTau, pTau, and Aβ42. The CSF concentrations
of pTau and tTau were strongly correlated with each
other (Spearman test) (Figure 2(a)). A signiﬁcant correla-
tion between ERK1/2 and tTau and between ERK1/2 and
pTau was observed, when considering the whole sample
(Figure 2(b)), while such a correlation did not reach the sta-
tisticalsigniﬁcanceinanydiagnosticgroup.TheCSFERK1/2International Journal of Alzheimer’s Disease 5
0 500 1000 1500 2000
0
100
200
300
r = 0.933
P<0.0001
n = 95
tTau (pg/mL)
p
T
a
u
(
p
g
/
m
L
)
MCI-AD
AD MCI-stable
ND
(a)
MCI-AD
200 400 600
0
500
1000
1500
2000
AD MCI-stable
ND
r = 0.404
P = 0.0001
n = 86
LLOD
ERK1/2 (pg/mL)
t
T
a
u
(
p
g
/
m
L
)
(b)
Figure 2: Correlations between tTau and pTau and between tTau and ERK1/2. In the whole sample, the CSF concentrations of tTau were
signiﬁcantly correlated with (a) pTau and (b) ERK1/2. ERK1/2 measurements below the LLOD of the respective assay plate (n = 9) were
excluded from the Spearman correlation test.
Table 2: Analysis for correlations between ERK1/2 and classical biomarkers∗.
ERK1/2
Patients group CSF marker r P value P value summary
Whole sample (n = 86)#
Aβ1−42 −0.436 < 0.0001 Signiﬁcant
t-Tau 0.404 0.0001 Signiﬁcant
p-Tau 0.384 0.0003 Signiﬁcant
Age 0.0001 0.999 n.s.
ND (n = 14)#
Aβ1−42 −0.0242 0.9346 n.s.
t-Tau −0.174 0.5528 n.s.
p-Tau −0.0022 0.9941 n.s.
Age 0.0726 0.8052 n.s.
MCI-stable (n = 20)#
Aβ1−42 0.0947 0.6912 n.s.
t-Tau 0.399 0.0816 n.s.
p-Tau 0.433 0.0563 n.s.
Age 0.0845 0.7231 n.s.
MCI-AD (n = 20)#
Aβ1−42 −0.0992 0.6772 n.s.
t-Tau 0.325 0.1623 n.s.
p-Tau 0.0248 0.9173 n.s.
Age 0.171 0.4723 n.s.
AD (n = 32)#
Aβ1−42 −0.544 0.0013 Signiﬁcant
t-Tau 0.176 0.3343 n.s.
p-Tau 0.161 0.3789 n.s.
Age −0.136 0.457 n.s.
∗Spearman correlation coeﬃcients (r)a n dP values (two tailed) are indicated.
#ERK1/2 measurements below LLOD (n = 9) were excluded from the correlation analysis.
levels were negatively correlated with Aβ42 in the whole
sample and in the AD group. A summary of nonparametric
Spearman correlation analysis for ERK1/2 versus tTau, pTau,
and Aβ42 is shown in Table 2.
The measurements of the CSF biomarkers tTau, pTau,
and Aβ42 are known to show a substantial degree of
variationbetweendiﬀerentcenters[21].Whenweperformed
separate correlation analyses for the 2 centers involved in
this study, signiﬁcant negative correlations were observed
b e t w e e nE R K 1 / 2a n dA β42 in the samples from both sites
when no classiﬁcation into diagnostic groups was applied,
and in the AD group from Kuopio. ERK1/2 and tTau as well6 International Journal of Alzheimer’s Disease
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Figure 3: Scatterplots of MMSE scores plotted against CSF-ERK1/2 levels. (a) Whole sample (n = 77). (b) MCI-AD group (n = 20). (c)
AD patients (n = 28). (d) MCI-stable (n = 20). The Spearman correlation coeﬃcients (r) and the two-tailed P values are indicated. Those
samples with ERK1/2 measurements below LLOD were excluded from the analysis.
as ERK1/2 and pTau were signiﬁcantly correlated with each
other in the samples from Perugia when all subjects were
considered, but not in any of the diagnostic groups per se
(supplementary information, Table S1).
3.4. Correlation of CSF-ERK1/2 with MMSE. For 84 of the
subjects included in this study (AD: n = 29, MCI-AD: n =
21, MCI-stable: n = 25, ND: n = 9), MMSE scores as a mea-
sure for cognitive functions were available. 77 out of these
withcalculatedCSF-ERK1/2concentrationsabovetheLLOD
were subjected to correlation analysis. In the whole sample,
CSF-ERK1/2showedastatisticallysigniﬁcantnegativeSpear-
man correlation with the MMSE scores (Figure 3(a)). When
the AD-, MCI-AD-, and MCI-stable groups were analyzed
individually, a signiﬁcant negative Spearman correlation
between MMSE scores and CSF-ERK1/2 was observed only
in the MCI-AD group (Figure 3(b)) but not in the AD group
or the stable MCI patients (Figures 3(c) and 3(d)).
3.5. Receiver-Operator Characteristic Curves. To evaluate the
possibility to use CSF-ERK1/2 levels for the discrimination
between relevant diagnostic groups, receiver-operator char-
acteristic curves (ROC curves) were calculated. Figure 4(a)
shows the ROC curves for ERK1/2, tTau, pTau, and Aβ42
for the discrimination of AD from ND, Figure 4(b) for the
discrimination of MCI-AD from stable MCI. The calculated
areas under the curves (AUCs) indicate that as single
biomarkers tTau, pTau, and Aβ42 were clearly superior to
CSF-ERK1/2.
3.6. Immunoblot Analysis of Prefractionated CSF. To provide
additional information regarding the ERK1/2 isoform(s)
contributing to the signals detected by the ERK1/2 electro-
chemiluminescence assay, a pooled CSF sample was pre-
fractionated by oﬀ-gel isoelectric focusing to facilitate the
subsequent Western blot analysis. The fractions covering
the pH range from ∼6.5 to ∼8.5 were combined andInternational Journal of Alzheimer’s Disease 7
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Figure 4: ROC curves for CSF-ERK1/2 levels and classical biomarkers: (a) ROC curves for Aβ42, tTau, pTau, and ERK1/2 (at baseline) for
the discrimination between ND and AD. (b) ROC curves for Aβ42, tTau, pTau, and ERK1/2 (at baseline) for the discrimination between
MCI-stable and MCI-AD. AUC: area under the curve. ERK1/2 measurements below LLOD are reported as 39pg/mL in (a) and (b).
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Figure 5: Detection of ERK1, ERK2, and doubly phosphorylated ERK2 in a pooled human CSF sample. Following prefractionation of
3.25mL of pooled CSF on an Oﬀ-gel fractionator, the proteins with isoelectric points in the pH range from ∼6.5 to ∼8.5 were pooled,
precipitated with trichloroacetic acid, and analyzed by SDS-PAGE/Western blot with the indicated antibodies. A sample corresponding to
∼0.54mL of the original CSF-pool was loaded on each lane. (1) Magic mark protein standard, (2) CSF pool, (3) positive control (cell lysate
of okadaic-acid-treated SH-SY5Y cells).
separated by SDS-polyacrylamide-gel electrophoresis fol-
lowed by Western blotting. Probing with a panel of anti-ERK
antibodies revealed the presence of ERK1, ERK2, and doubly
phosphorylated ERK2 in the pooled human CSF (Figure 5).
VisualcomparisonofthebandintensitiesinpooledCSFwith
those obtained with a lysate from SH-SY5Y cells loaded as
a positive control suggested that ERK2 was more abundant
than ERK1.
4. Discussion
In the present study, we have conﬁrmed our previous ﬁnding
of measurable levels of the MAP kinase ERK1/2 in human
CSF [8], and we have applied the methods established in that
previousworktoevaluatetheCSF-ERK1/2 concentrationsin
an age-matched sample including AD patients, MCI patients
who converted to AD during followup (MCI-AD), MCI
patients who remained stable, and a nondemented reference
cohort. As a group, the AD patients showed signiﬁcantly
higher CSF-ERK1/2 levels than the MCI-stable group and
the nondemented reference cohort. The individual ERK1/2
concentrations in the CSF samples displayed substantial
overlap between the diagnostic groups, and as a single
biomarker, CSF-ERK1/2 was clearly inferior to the classical
AD biomarkers tTau, pTau, and Aβ42, as is obvious from the
ROC curves shown in Figure 4.
In line with published biomarker studies [4, 22], in our
sample, Aβ42, tTau and pTau, in CSF were signiﬁcantly
altered at baseline in those MCI patients who later converted
to AD (supplementary information, Figure S1). This was
not the case for CSF-ERK1/2. In the AD group, but
not in the MCI-AD patients, CSF-ERK1/2 was statistically
signiﬁcantly elevated as compared to the ND and MCI-
stable groups. Therefore, it appears that the increase in CSF-
ERK1/2 may possibly occur at a later disease stage than
those of tTau and pTau. In the whole sample, CSF-ERK1/2
was signiﬁcantly correlated with the CSF concentrations
of tTau and pTau and negatively correlated with Aβ42. A
correlationbetweenERK1/2andtTauhadalsobeenobserved
in our previous study in a small set of CSF samples from8 International Journal of Alzheimer’s Disease
patients with diﬀerent neuropsychiatric disorders [8]. A
simple explanation could be that both proteins are released
in parallel when neurons degenerate. However, the observed
correlation between ERK1/2 and tau in the whole sample
in our present study was not particularly strong (Spearman
r = 0.404 as compared to r = 0.933 for the correlation
between pTau and tTau), and the association between the
two did not reach statistical signiﬁcance in any of the
diagnostic groups per se. To gain more insight whether the
increase in CSF-ERK1/2 in AD represents simply another
marker of neuronal destruction in addition to Tau, or if
possibly diﬀerent cell populations or distinct underlying
molecular mechanisms are reﬂected, it might be interesting
tomeasureCSF-ERK1/2levelsinpatientswithothernon-AD
neurodegenerative disorders. In a recent study, a statistically
signiﬁcant correlation between the CSF levels of tTau and
ERK1/2 was not observed in patients with Creutzfeldt-Jakob
disease [23]. Interestingly, in our current study, we found a
negative association of baseline CSF-ERK1/2 and the MMSE
scores in the MCI-AD group. Provided these ﬁndings can
be conﬁrmed in a larger sample, and possibly also with
other measures of cognitive function, we believe that our
preliminary results suggest that the change in CSF-ERK1/2
occurs later than those of Tau and Aβ42. One can therefore
speculate that in the long run, CSF-ERK1/2 may turn out to
be of interest as a biomarker sensitive to disease progression
at the MCI stage. Whether or not the ApoE genotype has an
impact on the CSF-ERK1/2 levels has to remain open at this
stagesincealargersamplesizewillberequiredforreasonable
statistical evaluation.
The mitogen-activated protein/extracellular signal-regu-
lated kinases ERK1 and ERK2 are ubiquitous components
of cellular signal transduction pathways regulating diverse
downstream processes, including proliferation, diﬀerentia-
tion, survival, and apoptosis [24, 25]. In the adult brain,
ERKs are abundantly expressed and are involved in the
regulation of activity-dependent neuronal functions, such
as synaptic plasticity, long-term potentiation, long-term
depression, and cell survival (for reviews, see [26–28]).
All three mitogen-activated kinase (MAPK) pathways, ERK,
JNK and p38 pathways, were reported to be activated in
vulnerable neurons in AD brains and were proposed to play
an important role in the pathogenesis [29]. In agreement
with the observations in CSF from Creutzfeldt-Jakob disease
patients [23], we demonstrate herein the presence of both
isoforms, ERK1 and ERK2, in a pooled CSF sample. In
rat brains, diﬀerences in the regional distributions of these
2 ERK isoforms were reported [30]. We have furthermore
conﬁrmed our previous ﬁnding of detectable amounts of
the activated (i.e., doubly phosphorylated) form of ERK2
in pooled CSF. To gain further insight into pathogenic
and pathophysiological molecular changes, it might be
particularly interesting to address in future studies the
activation state of ERK1/2 in CSF from AD patients. An
essential prerequisite for this kind of study, however, will be
the availability of a highly sensitive and reliable assay for the
measurement of doubly phosphorylated ERK1/2.
Taken together, we report here a statistically signiﬁcant
elevation of CSF-ERK1/2 in AD patients as compared to
ND and MCI-stable subjects. As a predictive diagnostic tool,
CSF-ERK1/2 turned out to be inferior to the “classical” CSF
biomarkers tTau, pTau, and Aβ42. Although our ﬁndings
need to be conﬁrmed and extended in future studies, the
observations suggest that the increase in ERK-1/2 levels
may occur at a later stage during disease development or
progression than the changes of tTau, pTau, and Aβ42 in
CSF.
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